Curated News
By: NewsRamp Editorial Staff
September 10, 2025
Lantern Pharma's AI-Driven Cancer Therapies Featured on BioMedWire Podcast
TLDR
- Lantern Pharma's AI platform RADR accelerates cancer drug development, offering investors a competitive edge in precision oncology with three ongoing clinical trials.
- Lantern Pharma uses its RADR AI platform with machine learning and multiomic data to systematically reduce drug development costs and failure rates in oncology.
- Lantern Pharma's AI-driven approach to cancer therapy development aims to improve patient outcomes and make precision oncology more accessible worldwide.
- Lantern Pharma's CEO discusses using AI to transform neuro-oncology in a new BioMedWire podcast, highlighting innovative clinical stage drug candidates.
Impact - Why it Matters
This news matters because it highlights the growing role of artificial intelligence in revolutionizing cancer treatment, potentially leading to faster, more effective, and less expensive drug development. For patients, this could mean quicker access to targeted therapies and improved outcomes, while investors and the healthcare industry benefit from advancements that reduce the high costs and failure rates traditionally associated with oncology research. The broader adoption of AI in medicine, as demonstrated by Lantern Pharma, represents a significant shift toward precision oncology, offering hope for more personalized and efficient cancer care in the future.
Summary
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company, is featured in the latest episode of IBN's BioMedWire Podcast, where President, CEO and Director Panna Sharma discusses the company's mission to accelerate cancer drug development using its proprietary RADR® AI platform. The platform leverages machine learning and multiomic data to address complex drug development challenges, aiming to transform the cost, time, and failure rate of oncology drug discovery. Sharma outlines progress across three ongoing clinical trials and shares insights on the future of precision neuro-oncology, highlighting Lantern's pipeline of clinical-stage drug candidates targeting novel cancer mechanisms.
BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, provides extensive distribution services, including access to wire solutions, article syndication to over 5,000 outlets, enhanced press release features, and social media distribution to millions of followers. This platform ensures that news from companies like Lantern Pharma reaches a wide audience of investors, influencers, and the general public, cutting through information overload to deliver breaking news and actionable content in the biotechnology and life sciences sectors.
For further details, the full press release is available at https://ibn.fm/ITg2o, and ongoing updates about Lantern Pharma can be found in the company's newsroom at https://ibn.fm/LTRN. BioMedWire's comprehensive approach, powered by IBN, supports corporate communications with tailored solutions, making it a key player in disseminating critical developments in biomedical innovation.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma's AI-Driven Cancer Therapies Featured on BioMedWire Podcast
